{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:23:40Z","timestamp":1760145820319,"version":"build-2065373602"},"reference-count":38,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Medicine and Pharmacy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>The treatment paradigm of multiple myeloma (MM) has shifted in the past years, as continuous therapy is becoming the standard of care for both newly diagnosed and relapsed patients. Although it is indisputable that continuous therapy has added a great benefit on the progression-free as well as overall survival, it is still unclear what the patients\u2019 perspective is on this therapeutic approach. Methods: This study included 155 adult MM patients from Fundeni Clinical Institute in Romania, receiving continuous therapy with daratumumab, proteasome inhibitors, immunomodulators, or bi-specific antibodies. The patients had varied economic, social, and educational backgrounds. We developed a questionnaire to interrogate the quantitative and qualitative effect of the therapy on the patients\u2019 personal and professional life and to identify the side effects that had the strongest impact on their quality of life. Results: 74.83% of the patients reported that the treatment they received negatively impacted their quality of life. Among them, 40% considered that the most detrimental aspects of the therapy are the financial burden and the negative impact on their professional life. One-third of the patients reported that the therapy negatively impacted their personal life and that it had a deleterious effect on their relationship with their partner and family members. In terms of the side effects experienced, patients considered that tiredness was the main factor causing a decrease in their quality of life, followed by insomnia and bone pain. Despite this, almost none of the patients considered dropping the therapy, and almost half of the patients considered that the frequent visits to the hospital offered them psychological comfort. In addition, more than 70% of the patients declared that they were afraid to stop the therapy if given the choice, with the main concerns being the fear of an early relapse. Conclusions: Although continuous therapy is associated with a high financial burden and a negative impact on both professional and personal life, the frequent visits to the hospital appear to be reassuring. Moreover, the patients would not opt for treatment discontinuation and felt safer when monitored frequently.<\/jats:p>","DOI":"10.3390\/jpm14090910","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T03:57:06Z","timestamp":1724817426000},"page":"910","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Perspective of Romanian Patients on Continuous Therapy for Multiple Myeloma"],"prefix":"10.3390","volume":"14","author":[{"given":"Ruxandra","family":"Irimia","sequence":"first","affiliation":[{"name":"Department of Hematology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 030167 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1507-2547","authenticated-orcid":false,"given":"Sorina Nicoleta","family":"Badelita","sequence":"additional","affiliation":[{"name":"Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sinziana","family":"Barbu","sequence":"additional","affiliation":[{"name":"Department of Hematology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 030167 Bucharest, Romania"},{"name":"Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larisa","family":"Zidaru","sequence":"additional","affiliation":[{"name":"Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioana Loredana","family":"Carlan","sequence":"additional","affiliation":[{"name":"Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oana Diana","family":"Preda","sequence":"additional","affiliation":[{"name":"Department of Hematology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 030167 Bucharest, Romania"},{"name":"Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Coriu","sequence":"additional","affiliation":[{"name":"Department of Hematology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 030167 Bucharest, Romania"},{"name":"Fundeni Clinical Institute, 022328 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Eisfeld, C., Kaj\u00fcter, H., M\u00f6ller, L., Wellmann, I., Shumilov, E., and Stang, A. (2023). Time trends in survival and causes of death in multiple myeloma: A population-based study from Germany. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-10787-5"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"m3176","DOI":"10.1136\/bmj.m3176","article-title":"Emerging immunotherapies in multiple myeloma","volume":"370","author":"Shah","year":"2020","journal-title":"BMJ"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2991\/chi.d.191101.001","article-title":"Moving Toward Continuous Therapy in Multiple Myeloma","volume":"1","author":"Bonello","year":"2019","journal-title":"Clin. Hematol. Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/asheducation-2017.1.212","article-title":"Fixed duration vs continuous therapy in multiple myeloma","volume":"2017","author":"Ludwig","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Progr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-020-0273-x","article-title":"Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/14737140.2018.1490181","article-title":"Maintenance and continuous therapy for multiple myeloma","volume":"18","author":"Richardson","year":"2018","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/pon.5054","article-title":"Quality of life versus length of life considerations in cancer patients: A systematic literature review","volume":"28","author":"Shrestha","year":"2019","journal-title":"Psychooncology"},{"key":"ref_10","unstructured":"(2023, August 01). WHOQOL\u2014Measuring Quality of Life|The World Health Organization. Available online: https:\/\/www.who.int\/tools\/whoqol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2147\/PPA.S261615","article-title":"Taking into Account Patient Preferences: A Consensus Study on the Assessment of Psychological Dimensions Within Patient Preference Studies","volume":"15","author":"Russo","year":"2021","journal-title":"Patient Prefer. Adherence"},{"key":"ref_12","first-page":"83","article-title":"Treat patient, not just the disease: Holistic needs assessment for haematological cancer patients","volume":"12","author":"Islam","year":"2018","journal-title":"Oncol. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-0609.2009.01250.x","article-title":"Health related quality of life in a nationally representative sample of haematological patients","volume":"83","author":"Johnsen","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Janssens, R., Lang, T., Vallejo, A., Galinsky, J., Morgan, K., Plate, A., De Ronne, C., Verschueren, M., Schoefs, E., and Vanhellemont, A. (2022). What matters most to patients with multiple myeloma? A Pan-European patient preference study. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1027353"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1080\/10428194.2021.1941927","article-title":"Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma","volume":"62","author":"Siegel","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Myeloma Trialists\u2019 Collaborative Group (2001). Interferon as therapy for multiple myeloma: An individual patient data overview of 24 randomized trials and 4012 patients. Br. J. Haematol., 113, 1020\u20131034.","DOI":"10.1046\/j.1365-2141.2001.02857.x"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1002\/cam4.5239","article-title":"Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant","volume":"12","author":"Ailawadhi","year":"2023","journal-title":"Cancer Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"100003","DOI":"10.1016\/j.bneo.2024.100003","article-title":"Real-world comparison of daratumumab-based regimens in relapsed\/refractory multiple myeloma using health record data","volume":"1","author":"Derman","year":"2024","journal-title":"Blood Neoplasia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s00277-023-05188-4","article-title":"Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients \u2013 real world evidence analysis","volume":"102","author":"Stork","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Irimia, R., Badelita, S.N., Barbu, S., Zidaru, L., Carlan, I.L., and Coriu, D. (2024). The Efficacy of Carfilzomib Treatment in Bortezomib-Refractory Patients-Real Life Experience in a Tertiary Romanian Hospital. J. Clin. Med., 13.","DOI":"10.3390\/jcm13082171"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1200\/JCO.2014.60.2466","article-title":"Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-018-0141-0","article-title":"Interpreting clinical trial data in multiple myeloma: Translating findings to the real-world setting","volume":"8","author":"Richardson","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"101532","DOI":"10.1016\/j.tranon.2022.101532","article-title":"Current perspectives on interethnic variability in multiple myeloma: Single cell technology, population pharmacogenetics and molecular signal transduction","volume":"25","author":"Gandhi","year":"2022","journal-title":"Trans. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1080\/14740338.2017.1361404","article-title":"Impact of pharmacogenomics upon the therapeutic response to etanercept in psoriasis and psoriatic arthritis","volume":"16","author":"Murdaca","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Sanz-Solas, A., Labrador, J., Alcaraz, R., Cuevas, B., Vinuesa, R., Cuevas, M.V., and Saiz-Rodr\u00edguez, M. (2023). Bortezomib Pharmacogenetic Biomarkers for the Treatment of Multiple Myeloma: Review and Future Perspectives. J. Pers. Med., 13.","DOI":"10.3390\/jpm13040695"},{"key":"ref_27","unstructured":"Yach, D. (2003). Adherence to Long-Term Therapies, World Health Organization. Available online: http:\/\/apps.who.int\/iris\/bitstream\/10665\/42682\/1\/9241545992.pdf."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/17474086.2019.1634541","article-title":"Quality of life outcomes in multiple myeloma patients: A summary of recent clinical trials","volume":"12","author":"Martino","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.clml.2019.04.018","article-title":"Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups","volume":"19","author":"Orlowski","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/sj.bjc.6600798","article-title":"Association of perceived physician communication style with patient satisfaction, distress, cancer-related self-efficacy, and perceived control over the disease","volume":"88","author":"Zachariae","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(00)04169-6","article-title":"Influence of context effects on health outcomes: A systematic review","volume":"357","author":"Harkness","year":"2001","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41375-020-01016-0","article-title":"Multiple myeloma gammopathies Recommendations for vaccination in multiple myeloma: A consensus of the European Myeloma Network","volume":"35","author":"Ludwig","year":"2021","journal-title":"Leukemia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1002\/ajh.26766","article-title":"Prevention of infections including vaccination strategies in multiple myeloma","volume":"98","author":"Ludwig","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41416-020-0866-y","article-title":"Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): An exploratory randomised Phase 2 trial utilising a modified Zelen design","volume":"123","author":"Koutoukidis","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6528","DOI":"10.1182\/blood-2023-177690","article-title":"Patient and Physician Preferences for Fixed-Duration Vs Treatment to Progression Chronic Lymphocytic Leukemia (CLL) Treatments: Results from a Multi-Country Discrete Choice Experiment","volume":"142","author":"Sile","year":"2023","journal-title":"Blood"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/14\/9\/910\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:43:58Z","timestamp":1760111038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/14\/9\/910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["jpm14090910"],"URL":"https:\/\/doi.org\/10.3390\/jpm14090910","relation":{},"ISSN":["2075-4426"],"issn-type":[{"type":"electronic","value":"2075-4426"}],"subject":[],"published":{"date-parts":[[2024,8,28]]}}}